Acumen director granted RSUs and stock options
Acumen Pharmaceuticals director John A. Stalfort III received new equity awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Acumen Pharmaceuticals director John A. Stalfort III received new equity awards. On June 3, 2026, he was granted 35,500 restricted stock units, each representing one share of common stock, and 53,250 stock options with an exercise price of $2.29 per share.
The RSUs and the option grant will vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, as long as he continues to serve through that date. Following these awards, he directly holds 220,624 shares of common stock.
Insider Trade Summary
Grant/Award: 88,750 shares
Grant/Award
2 txns
Insider
Stalfort John A III
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 53,250 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 35,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 53,250 contracts (Direct);
Common Stock — 220,624 shares (Direct)
Footnotes (2)
- F1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
- F2. The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Key Figures
RSU grant: 35,500 RSUs
Option grant size: 53,250 options
Option exercise price: $2.29 per share
+2 more
5 metrics
RSU grant
35,500 RSUs
Awarded June 3, 2026 to director
Option grant size
53,250 options
Stock Option (right to buy) granted June 3, 2026
Option exercise price
$2.29 per share
Conversion/exercise price for 53,250 options
Common shares after grant
220,624 shares
Total common stock directly held following RSU award
Option expiration
June 3, 2036
Expiration date of 53,250 stock options
Key Terms
restricted stock unit ("RSU"), contingent right, Stock Option (right to buy), vest in full, +1 more
5 terms
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right..."
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."
Stock Option (right to buy) financial
"Stock Option (right to buy)"
vest in full financial
"The RSUs will vest in full on the earlier of the first anniversary of the date of grant..."
annual stockholder meeting financial
"...on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting..."
An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Acumen Pharmaceuticals (ABOS) director John A. Stalfort III receive in this Form 4?
He received equity compensation grants, not open-market trades. The filing shows 35,500 restricted stock units and 53,250 stock options, both awarded on June 3, 2026, as part of his service on Acumen Pharmaceuticals’ board of directors.
How many restricted stock units were granted to the Acumen Pharmaceuticals (ABOS) director?
He was granted 35,500 restricted stock units. Each RSU represents a contingent right to receive one share of Acumen Pharmaceuticals common stock, subject to vesting conditions tied to continued service and the timing of the 2027 annual stockholder meeting.
What are the terms of the stock options granted to the Acumen Pharmaceuticals (ABOS) director?
He received 53,250 stock options with an exercise price of $2.29 per share. These options vest in full on the earlier of the first anniversary of June 3, 2026, or the 2027 annual stockholder meeting, provided he continues serving until vesting.
When do the new RSU and option awards for Acumen Pharmaceuticals (ABOS) vest?
Both the RSUs and options vest in a single cliff. Vesting occurs on the earlier of the first anniversary of the June 3, 2026 grant date or the 2027 annual stockholder meeting, assuming the director’s continuous service through that date.
Do these Acumen Pharmaceuticals (ABOS) Form 4 transactions involve any stock sales?
No, the Form 4 only reports acquisitions through equity awards. The transactions are coded as grants or awards of RSUs and stock options, with no open-market purchases or sales and no dispositions for tax withholding or gifting reported in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates